Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice
- PMID: 28596109
- DOI: 10.1016/j.jhep.2017.05.022
Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice
Abstract
Background & aims: Macrophages play vital roles in chronic liver injury, and have been tested as a tool for cytotherapy in liver fibrosis. However, macrophages possess ontogenic and functional heterogeneities. Some subsets are pro-fibrotic, whereas others are anti-fibrotic. This study aimed to clarify which macrophage subset is efficient for cytotherapy in liver fibrosis and to elucidate the underlying mechanisms.
Methods: Liver fibrosis was induced in mice by carbon tetrachloride injection or bile duct ligation. Bone-marrow-derived macrophages (BMDMs) were polarized into M0, M1, or M2 macrophages, respectively. BMDMs were infused into mice through the tail vein at different stages of fibrogenesis. Fibrosis progression, hepatic cell populations, and related molecular changes were evaluated.
Results: Both M0 and M1 BMDMs significantly ameliorated liver fibrosis, but M1 exhibited stronger therapeutic effects than M0. M2 macrophages were not effective on liver fibrosis. M1 macrophages reduced the number and activation of hepatic stellate cells (HSCs), which could be attributed at least partly to increased HSC apoptosis. M1 macrophages enhanced the recruitment of endogenous macrophages into fibrotic liver, which displayed the phenotype of Ly6Clo restorative macrophages and produced matrix metalloproteinases (MMPs) and hepatic growth factor (HGF) to enhance collagen degradation and hepatocyte proliferation, respectively. M1 macrophages also increased the number of total and activated natural killer (NK) cells in the fibrotic liver, which released TNF-related apoptosis-inducing ligand (TRAIL), inducing HSC apoptosis.
Conclusions: M1 macrophages, which modulate the immune microenvironment to recruit and modify the activation of endogenous macrophages and NK cells, are effective for cytotherapy in experimental liver fibrosis. Lay summary: M1 Bone marrow-derived macrophages (BMDMs) exhibit a stronger therapeutic effect by modulating the hepatic microenvironment to recruit and modify the activation of endogenous macrophages and natural killer (NK) cells, which likely lead to hepatic stellate cells (HSCs) apoptosis and hampered fibrogenesis.
Keywords: Cytotherapy; Hepatic stellate cells; Liver fibrosis; Macrophages; Polarization.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Comment in
-
Reply to: "Studies of macrophage therapy for cirrhosis - From mice to men".J Hepatol. 2018 May;68(5):1091-1093. doi: 10.1016/j.jhep.2017.12.024. Epub 2018 Jan 6. J Hepatol. 2018. PMID: 29317296 No abstract available.
-
Studies of macrophage therapy for cirrhosis - From mice to men.J Hepatol. 2018 May;68(5):1090-1091. doi: 10.1016/j.jhep.2017.11.043. Epub 2018 Jan 6. J Hepatol. 2018. PMID: 29317297 No abstract available.
Similar articles
-
Sphingosine Kinase 1 Aggravates Liver Fibrosis by Mediating Macrophage Recruitment and Polarization.Cell Mol Gastroenterol Hepatol. 2024;18(6):101406. doi: 10.1016/j.jcmgh.2024.101406. Epub 2024 Sep 19. Cell Mol Gastroenterol Hepatol. 2024. PMID: 39305988 Free PMC article.
-
Treatment with 4-methylpyrazole modulated stellate cells and natural killer cells and ameliorated liver fibrosis in mice.PLoS One. 2015 May 29;10(5):e0127946. doi: 10.1371/journal.pone.0127946. eCollection 2015. PLoS One. 2015. PMID: 26024318 Free PMC article.
-
CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation.J Autoimmun. 2010 Dec;35(4):424-35. doi: 10.1016/j.jaut.2010.09.003. Epub 2010 Oct 6. J Autoimmun. 2010. PMID: 20932719 Free PMC article.
-
Interaction of hepatic stellate cells with diverse types of immune cells: foe or friend?J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:99-104. doi: 10.1111/jgh.12017. J Gastroenterol Hepatol. 2013. PMID: 23855303 Review.
-
Monocytes and macrophages as cellular targets in liver fibrosis.Inflamm Allergy Drug Targets. 2009 Sep;8(4):307-18. doi: 10.2174/187152809789352230. Inflamm Allergy Drug Targets. 2009. PMID: 19534673 Review.
Cited by
-
FGF4 ameliorates the liver inflammation by reducing M1 macrophage polarization in experimental autoimmune hepatitis.J Transl Med. 2024 Aug 2;22(1):717. doi: 10.1186/s12967-024-05219-2. J Transl Med. 2024. PMID: 39095789 Free PMC article.
-
Mesenchymal stem cell-derived exosomes protect against liver fibrosis via delivering miR-148a to target KLF6/STAT3 pathway in macrophages.Stem Cell Res Ther. 2022 Jul 20;13(1):330. doi: 10.1186/s13287-022-03010-y. Stem Cell Res Ther. 2022. PMID: 35858897 Free PMC article.
-
The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective.Cells. 2021 Oct 30;10(11):2959. doi: 10.3390/cells10112959. Cells. 2021. PMID: 34831182 Free PMC article. Review.
-
Depleting profibrotic macrophages using bioactivated in vivo assembly peptides ameliorates kidney fibrosis.Cell Mol Immunol. 2024 Aug;21(8):826-841. doi: 10.1038/s41423-024-01190-6. Epub 2024 Jun 13. Cell Mol Immunol. 2024. PMID: 38871810 Free PMC article.
-
Effect of miR-183-5p on Cholestatic Liver Fibrosis by Regulating Fork Head Box Protein O1 Expression.Front Physiol. 2021 Nov 18;12:737313. doi: 10.3389/fphys.2021.737313. eCollection 2021. Front Physiol. 2021. PMID: 34867446 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical